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Abstract: High-grade gliomas are still characterized by a poor prognosis, despite recent
advances in surgical treatment. Chemotherapy is currently practiced after surgery, but its
efficacy is limited by aspecific toxicity on healthy cells, tumour cell chemoresistance, poor
selectivity, and especially by the blood–brain barrier (BBB). Thus, despite the large number
of potential drug candidates, the choice of effective chemotherapeutics is still limited to few
compounds. Malignant gliomas are characterized by high infiltration and neovascularization,
and leaky BBB (the so-called blood–brain tumour barrier); surgical resection is often
incomplete, leaving residual cells that are able to migrate and proliferate. Nanocarriers can
favour delivery of chemotherapeutics to brain tumours owing to different strategies, includ-
ing chemical stabilization of the drug in the bloodstream; passive targeting (because of the
leaky vascularization at the tumour site); inhibition of drug efflux mechanisms in endothelial
and cancer cells; and active targeting by exploiting carriers and receptors overexpressed at
the blood–brain tumour barrier. Within this concern, a suitable nanomedicine-based therapy
for gliomas should not be limited to cytotoxic agents, but also target the most important
pathogenetic mechanisms, including cell differentiation pathways and angiogenesis.
Moreover, the combinatorial approach of cell therapy plus nanomedicine strategies can
open new therapeutical opportunities. The major part of attempted preclinical approaches
on animal models involves active targeting with protein ligands, but, despite encouraging
results, a few number of nanomedicines reached clinical trials, and most of them include
drug-loaded nanocarriers free of targeting ligands, also because of safety and scalability
concerns.
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Classification of Brain Tumours
The most frequent brain tumours (gliomas) originate from glial cells, and range
from low infiltrating to highly aggressive. In the 2007 World Health Organization
(WHO) classified gliomas within four grades, basing on histopathologic features,
such as mitotic index, anaplasia, cytological atypia, microvascular proliferation, and
necrosis: grade I (ie pilocytic astrocytoma), grade II (ie astrocytomas and oligoden-
drogliomas), grade III (ie anaplastic astrocytomas and oligodendrogliomas), and
grade IV (ie glioblastoma multiforme). In 2016 WHO included in the classification
also molecular diagnostic criteria for infiltrating gliomas, including mutation of
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isocitrate dehydrogenase, deletion of 1p/19q chromosome,
and histone mutations.1 However, malignant or high grade
(III and IV) gliomas are characterized by very poor prog-
nosis. Furthermore, 8–10% of the adult patients with can-
cer develop brain metastases, with considerably variable
incidence among different primary cancers. Lung, breast,
colon, kidney cancer or melanoma can lead to brain metas-
tases, 70% of which originating from lung and breast
cancer.2
Current Therapy of Gliomas
Surgery is the first-line treatment both in low and high-
grade gliomas3 and the extent of resection has demon-
strated a positive prognostic effect.4 Several techniques
have been designed to refine tumour resection: neuronavi-
gation, use of 5-aminolevulinic acid,5 and intra-operative
magnetic resonance imaging (MRI). There is evidence that
the combined use of these techniques improves the rate of
gross total resection. The choice and the timeframe of
subsequent adjuvant chemotherapy and radiation therapy
(alone or as combined treatments) is still considered con-
troversial. A survey within the European Low-Grade
Glioma Network showed a relevant heterogeneity in the
usage of chemotherapy. Generally, oral temozolomide
(TMZ) is the first-line treatment after surgery for high-
risk low-grade gliomas, or at progression, although,
according to the Radiation Therapy Oncology Group,
combination of radiotherapy with procarbazine, lomustine
and vincristine regimen has been indicated as the gold-
standard treatment.6 While investigations are currently
underway to evaluate the potential role of chemotherapy
in low-grade gliomas, combined chemotherapy/radiother-
apy approaches are currently practiced after surgery in
high-grade gliomas. Radiotherapy is related to important
side effects, such as post-radiation leuko-encephalopathy,
nerve damage, hair loss, vomiting, infertility, and skin
rash. Moreover, the effectiveness of chemotherapy is lim-
ited by toxic effects on healthy cells, tumour cell chemore-
sistance, and poor selectivity of anticancer drugs. Finally,
the blood–brain barrier (BBB) is the major limit for the
delivery of chemotherapeutic agents.7 Thus, the che-
motherapeutics currently employed for high-grade gliomas
are still limited to few chemical compounds. Currently,
owing to the Food and Drug Administration (FDA), oral
TMZ is the standard chemotherapy for glioblastoma and
anaplastic astrocytoma. Bevacizumab (Avastin®) is
a monoclonal antibody that specifically binds vascular
endothelial growth factor (VEGF). Despite FDA
accelerated approval for bevacizumab for brain tumours,
basing on its efficacy towards recurrent glioblastoma, its
use has been involved with many controversies. Indeed,
this anti-angiogenic therapy failed to improve patient over-
all survival, despite showing efficacy in shrinking or halt-
ing tumour growth.8 In 1996, FDA approved
biodegradable polyanhydride wafers loaded with carmus-
tine (Gliadel®) for chemotherapy of recurrent high-grade
gliomas. Patients with recurrent tumours benefit of an 8
weeks survival increase, when wafers were placed at
the second surgery. Instead, the survival increase was 2.3
months in patients with early diagnosed tumours, under-
going primary resection followed by wafer placement.9
Experimental Drugs for Gliomas
Apart from currently approved chemotherapy, several
drugs belonging to various therapeutic categories are cur-
rently under investigation for high-grade glioma treatment:
the main mechanisms underlying their activity towards
glioma are summarized in Figure 1. Advantages and dis-
advantages of such therapeutic drugs are listed in Table 1.
In the following sections, the most important attempts and
findings at preclinical and clinical level concerning such
drugs are briefly described.
Cytotoxic Agents
Different marketed cytotoxic drugs have been tested off-
label in preclinical glioma models and clinical trials,
including nitrosoureas (alkylating agents), platinum salts,
inhibitors of topoisomerase I (etoposide) and II (camp-
tothecin, irinotecan, topotecan), mitotic inhibitors that is
taxanes derivatives (paclitaxel, docetaxel), anthracyclines
such as doxorubicin (DNA intercalation and topoisome-
rase II inhibition), and paclitaxel–cisplatin–vincristine
(PCV) combination.10
Prodrugs of Cytotoxic Agents
Lipophilic prodrugs with molecular weight (MW) lower
than 500 Da, and capable of forming less than 8 hydrogen
bonds, should be able to overcome the BBB:11 the cyto-
toxic drug chlorambucil was modified accordingly, with
improved brain delivery.12 However, recent interest has
been growing concerning higher MW compounds, such
as fatty acid – paclitaxel (PTX) prodrugs. In particular cis-
linoleic acid conjugate with PTX (CLA-PTX) resulted in
much higher plasmatic half-life and brain accumulation
than free PTX, with encouraging therapeutic effect on
brain tumour bearing rats.13
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Angiogenesis Inhibitors
The expression level of VEGF directly correlates with
tumour grade, with a nearly 10-fold gap between high
and low-grade gliomas.14 Thus, endothelial cells are
a suitable target for high-grade glioma treatment. Apart
from monoclonal antibody bevacizumab, that selectively
binds VEGF, potential therapeutic agents include thali-
domide and VEGF receptor (VEGFR) inhibitors,
belonging to receptor tyrosine kinase (RTK) inhibitors
category.15 Cediranib and vatalanib are orally bioavail-
able VEGFR inhibitors, with simultaneous inhibitory
activity on tyrosine-protein kinase KIT (c-Kit) and pla-
telet-derived growth factor receptor (PDGFR), that, cur-
rently, are undergoing clinical trials for high-grade
gliomas.16
Epidermal Growth Factor Receptor
(EGFR) Inhibitors
EGFR, together with downstream signalling pathways
(such as phosphoinositide 3-kinase/protein kinase B/mam-
malian target of rapamycin - PI3K/Akt/mTOR and Ras
mitogen-activated protein kinase - Ras/MAPK), regulates
cell survival, proliferation, angiogenesis and migration.
EGFR is overexpressed in over 40% of glioblastomas.17
Furthermore, 25% of glioblastomas are characterized by
the expression of an EGFR mutant (EGFRvIII), which is
defective of the extracellular ligand-binding domain.18
Erlotinib, lapatinib, and gefitinib, three RTK inhibitors
acting on EGFR, have been tested at preclinical and clin-
ical stage for malignant gliomas treatment, with limited
efficacy.15 Also, cetuximab and nimotuzumab, two mouse
Figure 1 Main mechanisms of experimental drugs used against high-grade gliomas.
Abbreviations: avß3/avß5, avß3/avß5 heterodimers; EGFR, epidermal growth factor receptor; EGFRvIII, mutant EGFR; MMP, matrix metalloproteinase; PDGFR, platelet-
derived growth factor receptor; PI3K/Akt/mTOR, phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin; PKC, protein kinase C; PTEN, phosphatase
and tensin homolog; Ras/MAPK, Ras mitogen-activated protein kinase; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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Table 1 Advantages and Disadvantages of Experimental Drugs Against High-Grade Gliomas
Advantages Disadvantages
Cytotoxic
agents
● Complete oral bioavailability of TMZ149
● Capacity of nitrosoureas and temozolomide to cross the
BBB
● Clinical efficacy of nitrosoureas chemotherapy combined
with radiotherapy150
● Clinical efficacy of the combination of etoposide and
platinum salts149
● Availability of newer platinum derivatives (eg oxaliplatin)
with activity against resistant tumors10
● Important side effects: nausea, myelosuppression, hepatotoxi-
city, DOX cardiotoxicity, cisplatin nephrotoxicity, etc
● Generally i.v. administered
VEGFR
inhibitors
● Orally administered
● Potential availability of biomarkers indicative of tumour
responsiveness to VEGF inhibition151
● Vascular normalization induced may reduce interstitial
fluid pressure and allow better drug penetration16
● Reduced tumour hypoxia16
● Well tolerated
● Continued tumour growth in monotherapy152
Anti-VEGF
antibodies
● Size reduction in xenograft models153
● Good clinical efficacy also in monotherapy154
● Severe toxicities, especially in combination with irinotecan71
● i.v. administration
EGFR inhibitors ● Potential identification of EGFR inhibition sensitive
phenotypes155
● Limited efficacy both as mono and combination therapy, or
radiotherapy9
● Severe toxicities9
Anti-EGFR
antibodies
● Orally administered
● Binding to both wild-type and EGFRvIII receptors18
● Increased survival in combination with radiotherapy in
mouse models157
● Responsiveness as monotherapy in EGFR overexpressing
patients refractory to standard chemotherapy158
● Well tolerated
● No difference in survival between normal and EGFR over-
expressing patients156
● i.v. administration
PDGFR
inhibitors
● Orally administered
● Promising direct antitumor activity in preclinical models159
● Sensitize glioma cells to radiation159
● Through vascular normalization, it facilitates the tumor
penetration of cytotoxic drugs159
● Well tolerated
● Poor clinical efficacy as monotherapy9
Ras/MAPK
inhibitors
● Orally administered
● Safety and efficacy of tipifarnib in combination therapy9
● No clinical efficacy of tipifarnib monotherapy160
PKC inhibitors ● Orally administered
● Well tolerated and promising efficacy in highly pretreated
patients161
● High doses are poorly tolerated with cardiovascular side
effects162
PI3K/Akt/
mTOR
inhibitors
● Everolimus and sirolimus orally administered
● Tumor growth was retarded in some patients34
● Well tolerated
● Significant activation of Akt, potentially resulting in a reduced
time to progression34
● No clinical efficacy as monotherapy163
Multi target
inhibitors
● Multiple target inhibition with a single agent
● Pazopanib, sorafenib, sunitinib, tandutinib, vandetanib
orally administered
● Sorafenib overcomes BBB164
● No clinical benefit as monotherapy9
(Continued)
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anti-human EGFR antibodies, were employed in clinical
trials for recurrent high-grade glioma patients.9,19
PDGFR Inhibitors
PDGFR is an RTK, which is overexpressed in more than
20% of glioblastomas,20 and, like EGFR, it is upstream of
Ras/MAPK and PI3K/Akt/mTOR signalling pathways.21
Imatinib, an inhibitor of PDGFR, c-Kit, Abelson murine
leukemia viral oncogene (Abl), and arginase (ARG), was
tested in several clinical studies involving high-grade
glioma patients.15,22
Ras/MAPK Inhibitors
The Ras/MAPK signalling pathway is downstream to sev-
eral RTK inhibitors, such as fibroblast growth factor recep-
tor (FGFR), insulin-like growth factor (IGFR), and the
aforementioned EGFR, VEGFR, PDGFR. Therefore, it is
responsible for cell proliferation and migration processes,
as well as for cell cycle progression, and malignant trans-
formation. Ras/MAPK is also upstream to PI3K/Akt/
mTOR signalling pathway.15,21,23 Furthermore, malignant
gliomas are characterized by Ras/MAPK up-regulation.23
Oral tipifarnib, a farnesyl transferase inhibitor with
demonstrated radio-sensitizing effect is currently under-
going several clinical trials for high-grade gliomas.24
Protein Kinase C (PKC) Inhibitors
PKC enzymes belong to a serine/threonine kinases family,
and it is downstream to different RTKs, including VEGFR
and PDGFR.25 PKC is involved in chemoresistance
and radioresistance in malignant gliomas .26 Furthermore,
PKC is frequently overexpressed in malignant gliomas.26–28
Enzastaurin, a lipophilic, orally administered PKC inhibitor,
underwent different clinical trials as mono or combination
therapy, but with limited clinical benefit.9
PI3K/Akt/mTOR Pathway Inhibitors
PI3K/Akt/mTOR is down-regulated by phosphatase and
tensin homolog (PTEN), which, in turn, is altered (deleted,
inactivated, or mutated) in nearly 40–70%
glioblastomas.29,30 Sirolimus, an orally bioavailable pep-
tide macrolide, which is able to overcome the BBB and
acts as mammalian target of rapamycin (mTOR) inhibitor,
is currently employed in clinical trials for malignant
gliomas.31 Also, everolimus and temsirolimus, two ana-
logs of sirolimus, respectively, orally and i.v administered,
have been tested in clinical trials.32,33 However, mTOR
inhibitors induce significant activation of protein kinase
B (Akt) in 50% of the patients, potentially causing
a reduced time to progression: simultaneous inhibition of
mTOR and Akt could overcome this limitation.34
Multi-Target Inhibitors
The simultaneous inhibition of different aberrant signal-
ling pathways should result in great clinical benefit for
targeted therapies. Apart from the combination of different
drug therapies, multiple-target inhibition can be achieved
through employment of small molecule inhibitors of
newer-generation.15 Dasatinib, pazopanib, sunitinib, sora-
fenib, vandetanib, tandutinib are currently in evaluation in
clinical trials for glioblastoma, alone or in combination
therapy.9
Matrix Metalloproteinase (MMP)
Inhibitors
MMPs are proteolytic enzymes active also in physiologi-
cal conditions. In tumours, they promote basal membrane
invasion, metastatization and angiogenesis, being directly
secreted by tumour cells or by the surrounding stroma,
under tumoural stimulus. Marimastat, the most studied
MMP inhibitor, showed promising in vitro inhibition of
Table 1 (Continued).
Advantages Disadvantages
MMP inhibitors ● MMP overexpression in gliomas ● Negligible clinical efficacy165
● Severe toxicities165
Integrin
inhibitors
● Minimal toxicity also at high doses166 ● Limited clinical efficacy as monotherapy166
Abbreviations: Akt, protein kinase B; BBB, blood–brain barrier; DOX, doxorubicin; EGFR, epidermal growth factor receptor; EGFRvIII, mutant EGFR; MMP, matrix
metalloproteinase; PDGFR, platelet-derived growth factor receptor; PI3K/Akt/mTOR, phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin; PKC,
protein kinase C; Ras/MAPK, Ras mitogen-activated protein kinase; TMZ, temozolomide; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth
factor receptor.
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malignant glioma, but no advantage in clinical trials with
glioblastoma patients.35,36
Integrin Inhibitors
The expression of avß3 and avß5 heterodimers is increased
in malignant gliomas, and it has been hypothesized that
they contribute to regulate angiogenesis and migration.37
Cilengitide is a potent antagonist of both avß3 and avß5.
Several clinical trials testing cilengitide in combination
therapy regimens are currently ongoing.9
Rationale for Employment of
Nanomedicines in Glioma Therapy
The main mechanisms underlying the rationale of employ-
ing nanomedicines for glioma treatment are summarized
below (Figure 2).
Passive Targeting
The permeability of adjacent brain vasculature changes
during the growth of brain tumours. At their early stage,
the growth of tumour cells depends only on normal brain
vessels and the BBB is intact. With tumour progression,
glioma cells invade the surrounding healthy tissues. When
a large enough volume (>0.2 mm3) is reached by the
tumour cell cluster, a structural damage will affect the
BBB, and blood–brain tumour barrier (BBTB) will be
formed.38 Within this concern, claudin-1, a protein specifi-
cally expressed in the tight junctions of endothelial cells, is
down-regulated in vessels surrounding high-grade gliomas,
thus increasing the permeability of the BBB.39,40 This
“leaky” BBTB is a common feature of high-grade gliomas,
because of their increased metabolic requirements.
Furthermore, it has been demonstrated that VEGF, asso-
ciated with the high angiogenic nature of high-grade
Figure 2 Rationale of employing nanomedicines for glioma treatment.
Abbreviations: BBB, blood–brain barrier; BBTB, blood–brain tumour barrier; CMT, carrier-mediated transport; EPR, enhanced permeation and retention; HIF, hypoxia-
induced factors; P-gp, P-glycoprotein; RMT, receptor-mediated transport.
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gliomas, increases the BBB permeability, by stimulating
angiogenesis in response to hypoxia.41,42 The “leaky”
BBTB can be targeted for drug delivery purposes, by
exploiting the so-called enhanced permeability and retention
(EPR) effect. Since the pores cut-off size at the BBTB is
highly variable, the size of nanocarriers largely influences
the extent and efficacy of drug delivery. In fact, the vascular
leakage is significantly reduced in the tumours within the
brain microenvironment compared with other districts, and
it is affected by the tumour stage and/or to the tumour
model employed.43 For instance, the critical cut-off size of
the BBTB for intracranial U87MG xenografts ranges
between 7 and 100 nm.44 Despite the reduced size of vessel
fenestrations may limit the potential of passive targeting
strategy to address brain cancer, drug-loaded nanocarriers
free of targeting ligands showed promising efficacy in
orthotopic brain glioma models, thus allowing
a translation to clinical therapy.45
Active Targeting
However, high-grade gliomas rapidly infiltrate the sur-
rounding healthy tissue, where the BBB is not altered
and the EPR effect cannot be achieved.46 Indeed, in
human patients, contrarily to animal tumour models, che-
motherapy is only adjuvant, and it should mainly be
addressed towards the eradication of residual tumour
cells after surgery or radiotherapy. This cell population
includes cells migrating from the tumour into healthy
tissue or that feed the tumour from distant sites still active.
Thus, the most relevant area for chemotherapy is the one
surrounding the glioma, the so-called BAT (Brain
Adjacent to Tumour), including cells in the invasion
phase, that do not still affect the integrity of the BBB.
Since BAT should be the main target of chemotherapy, the
development of formulations easily crossing the intact
BBB is essential.47 In this case, suitable active targeting
of nanocarriers is needed to reach the target tissue, by
exploiting carrier and/or receptors overexpressed at the
BBB. Carrier-mediated transporters (CMTs) are entailed
in the transport of essential small molecules into the brain.
Receptor-mediated transporters (RMTs) are abundantly
expressed at the BBB, being exploited by large endogen-
ous biomolecules.2,48 Specific peptide receptors are
included in RMT, eg low-density lipoprotein (LDL) recep-
tor, transferrin (Tf) receptor, lactoferrin (Lf) receptor, insu-
lin receptor, and receptors for insulin-like growth factors
(IGF-1 and IGF-2).49 CMT and RMT ligands have been
frequently exploited for drug delivery as molecular
“Trojan horses” for nanocarriers.50–55
Overcoming Extrusion Mechanisms at the
BBB
Additionally, in the BBB endothelial cells (on the luminal
side), as well as in glioma cells, the P-glycoprotein (P-gp)
is present. P-gp is a 170-kDa glycoprotein associated to
the cell membrane, belonging to the superfamily of ATP
binding cassette (ABC) transporters, that actively extrudes
from cells chemically different substrates. P-gp can ham-
per BBB overcoming by chemotherapeutic drugs, and it is
responsible for chemoresistance in glioma cells.56,57 Thus,
P-gp inhibition can be considered as a potential dual
strategy, suitable both to enhance drug penetration in the
brain, and to reduce glioma chemoresistance. Thus, speci-
fic inhibitors of ABC subfamily member 1, such as elacri-
dar and tariquidar, and anti-estrogen tamoxifen, were
investigated for glioma treatment, owing to their anti-ex-
trusion effect at the BBB.58,59 Apart from chemical mod-
ulators, also nanoparticulate systems can inhibit the P-gp
drug efflux mechanism: indeed they can deliver the drug
within the cells by endocytosis, therefore making it less
susceptible to the membrane-bound drug efflux mechan-
isms, since it is in the form of drug-matrix aggregates.
Also, some ingredients employed in the formulation of
nanocarriers, such as surfactants, can contribute to the
P-gp inhibition.60 Furthermore, co-delivery in the same
nanocarriers of cytotoxic drugs and P-gp inhibitors (such
as ketoconazole) has also been attempted in preclinical
models.61
Inhibition of Tumour Differentiation,
Migration and Neo-Vascularization
Lastly, from a histological point of view, in malignant
gliomas, areas of necrosis, hypoxia and microvascular
hyperplasia are present, with pseudo-palisades of cells
migrating from the original necrosis area.62,63
Accordingly, it has been recently shown that cancer stem
cells (CSC) are responsible for the initiation step of human
glioblastoma and medulloblastoma in intracranial mouse
xenografts.64 Unfortunately, the CSC location has yet to be
precisely disclosed, but it has been demonstrated that
hypoxia-induced factors (HIF) are responsible for CSC
phenotype and can even shift normal cells to CSC.65,66
Since HIF are involved both in angiogenesis and in main-
taining CSC, a suitable treatment for high-grade gliomas
Dovepress Ferraris et al
International Journal of Nanomedicine 2020:15 submit your manuscript | www.dovepress.com
DovePress
3005
should be able to down-regulate their expression. This can
occur by scavenging of reactive oxygen species (ROS).
Indeed, during hypoxia, rising intracellular ROS concen-
tration overcomes glutathione (GSH) guard levels. ROS
can stabilize HIF, allowing VEGF transcription and con-
sequent angiogenesis.67–70 This mechanism underlies the
rationale for employing anti-oxidant and anti-VEGF
agents in glioma therapy. Indeed, the combination of anti-
angiogenic bevacizumab and cytotoxic irinotecan is
approved for recurrent glioblastoma.71,72 Furthermore, in
mice bearing intracerebral glioblastoma, pre-treatment
with Tempol, a ROS scavenger, followed by TMZ che-
motherapy, suppressed tumour growth and increased sur-
vival rate.73 Within this concern, nanocarriers should be
able to achieve co-delivery of anti-VEGF drugs and anti-
oxidants, together to cytotoxic agents within the tumour
tissue, owing to the aforementioned mechanisms. A recent
experimental study showed an increase in bevacizumab
activity and permeation through the BBB, when loaded
within solid lipid nanoparticles (SLN).74 Also treatment
cerium oxide nanoparticles (nanoceria), with ROS scaven-
ging properties, caused decreased expression levels of
VEGF in a human astrocytoma cell line, associated with
reduced motility and capacity of endothelial cells to form
new capillaries.75 Recently, camptothecin (CPT),
a topoisomerase inhibitor, was employed in a co-delivery
nanoparticulate system, that could stop the stabilization of
HIF in brain tumours. For this, a suitable CPT prodrug was
synthesized, by linkage with a tetraethylene glycol (TEG)
spacer and α-lipoic acid (ALA). The obtained CPT-TEG-
ALA prodrug can be cleaved by oxidation, thus acting as
a ROS scavenger, and release CPT in its active form
within glioblastoma cells. CPT-TEG-ALA was loaded in
nanoemulsion along with α-tocopherol, an additional ROS
scavenger, thus preventing HIF production.76
Preclinical Nanomedicines
Several approaches involve the alteration of the BBB, in
order to increase brain penetration of nanocarriers loaded
with chemotherapeutic drugs against glioma tumours.
They include both invasive methods,77 such as convection-
enhanced delivery78,79 and post-surgical implantation,80–82
and noninvasive BBB opening through focused ultrasound
(FUS).83 Indeed, ultrasound with a frequency below 1
MHz can induce reversible and temporary BBB opening
with the aid of microbubbles (Figure 3). This technique
can be employed to deliver theranostic agents for the
detection and treatment of various brain diseases, and it
Figure 3 Scheme of brain delivery of nanoparticles with focused ultrasound (FUS) technique.
Abbreviation: SF6, sulfur hexafluoride.
Ferraris et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Nanomedicine 2020:153006
has been already subject of clinical trials.84 In particular,
Cu-Se ultrasmall nanoparticles and rare earth nanoparti-
cles, labelled with near-infrared (NIR) dyes, have been
employed, at preclinical level, to monitor FUS-induced
temporary opening of the BBB and following recovery,85
as well as to detect glioma in orthotopic animal models.86
In further studies, the aforementioned Cu-Se ultrasmall
nanoparticles, loaded with doxorubicin (DOX) and
labelled with NIR dyes, were used concurrently with
FUS and photodynamic therapy, and demonstrated good
efficacy against orthotopic tumour models.87
Anyway, the nanocarriers discussed here below include
only those used to overcome the BBB/BBTB without dis-
ruption, aiming to deliver anti-cancer drugs to the brain
tumours. They can be made of different matrixes, including
metals (ie calcium phosphate, iron oxide), lipids (SLN),
phospholipids (liposomes), proteins (bovine serum albumin –
BSA), synthetic polymers (ie poly-lactide – PLA; poly-
lactide-glycolide – PLGA; PEG: polyethyleneglycol), nat-
ural polymers (ie chitosan) and polymer-lipid hybrid nano-
particles (PLN).88
Requested features of such nanomedicines are the
following:46
● They should stabilize the drug from physicochemical
or biological standpoints;
● They should avoid opsonization and, therefore,
clearance by the reticuloendothelial system (RES),
prolonging plasma circulation time and allowing
EPR effect;
● They should be endowed with selective targeting
strategies to the brain;
● They should not stimulate immune response.
However, the fact that almost 98% of drugs are unable to
overcome the BBB is the main reason for employment of
nanocarriers in high-grade glioma treatment. Two
approaches have been documented in literature: the first
employs plain nanocarriers, the second exploits active
targeting, in order to enhance uptake of the nanocarriers
by the endothelial cells at the BBB/BBTB.89
Within this concern, a huge number of nanocarriers
aiming to glioma treatment have been engineered in the
last decades. However, the following discussion will be
focused only on the ones that underwent preclinical
in vivo testing. Indeed, despite the presence of several
in vitro investigation methods,90 only preclinical animal
models can be predictive of the real potential of
administered nanomedicines, because of the simultaneous
presence of biological barriers and metabolism/distribu-
tion. Pharmacokinetic and biodistribution experiments are
relevant in order to foresee the metabolic fate of nanocar-
riers and loaded drugs, while glioma models allow to
predict in vivo efficacy. Different mouse and rat glioma
models are described in literature:91 ethyl-nitrosourea
induced orthotopic models in allogeneic or syngeneic
healthy animals, orthotopic xenografts, or genetically engi-
neered models. Within this concern, it should be pointed
out that the glioma model employed can affect in
a relevant manner the measured efficacy of the therapeutic
drug delivery system under investigation, with the immune
system playing a key role. In fact, today the so-called
“immune privilege” of the brain is no more a retained
concept.92,93 Thus, if the absence of the immune system
could cause an under-estimation of the therapeutic effect
in xenografts, on the other side, the presence of the immu-
nity in immuno-competent models can hamper the repro-
ducibility of the glioma model itself. Indeed, the superior
reproducibility of syngeneic models over allogeneic has
been documented, owing to a lower graft rejection.94
Furthermore, despite surgical resection is the primary
approach for high-grade gliomas, the majority of preclini-
cal models focus solely on drug treatment of solid intra-
cranial tumours. Within this concern, recently a resection
and recurrence orthotopic model has been developed, with
potential for the investigation of tumour ablation com-
bined with local and systemic chemotherapy.95
Plain Nanocarriers
Plain nanocarriers can improve drug delivery to gliomas
by stabilizing the drug in the bloodstream, such as in the
case of TMZ, which suffer from pH-dependent nonenzy-
matic chemo-degradation at the neutral pH, despite being
the most employed drug for the treatment of brain cancers.
Published reports demonstrated the therapeutic advantage
of loading TMZ inside nanostructured lipid carriers
(NLC), which is an optimized form of SLN with higher
drug loading capacity.96,97 Naked nucleic acid delivery is
also associated with fast degradation, aspecific biodistribu-
tion and poor cell internalization. In fact, small interfering
RNA (siRNA) and microRNA (miRNA) are promising
tools to treat various diseases, but, due to their instability
and poor delivery within target tissues, naked RNA is not
robustly used. Thus, entrapment in positively charged
nanocarriers can prevent from degradation/metabolism,
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and favour cell internalization, both at the BBTB and in
glioma cells.98
Nanocarriers can also increase drug half-life (for EPR
effect), and/or favour endocytosis across BBTB endothe-
lial cells, also owing to P-gp inhibition. In particular, this
mechanism has been well documented for lipid nanocar-
riers, such as liposomes and SLN.99 The physiological
nature of the lipid matrix employed should improve nat-
ural brain uptake, and the employment of surfactants, such
as Brij 78 or Polysorbate 80, to coat SLN can improve the
nanoparticle brain uptake and drug activity, being the two
molecules associated to P-gp inhibition.100,101 However,
SLN mechanism of action excludes any significant toxic
effect on the BBB, as assessed by the absence of altera-
tions to cell integrity and permeability, vessel blood flow,
and choline active transport. Indeed, Western blot analyses
of occludin and claudin-1 in the BBB cells, run following
SLN administration, showed no modifications in protein
expression.102 Interestingly, in the case of the insoluble
prototype anticancer drug named edelfosine (EDF) and of
ion-paired idarubicin, also oral administration of drug-
loaded SLN was effective against glioma subcutaneous
models101 and in enhancing drug concentration in the
brain,103 respectively.
Finally, plain nanocarriers can also be employed for
stimuli-responsive formulations. Indeed, the combination
of silver nanoparticles (AgNPs) with magnetic nanoparti-
cle hyperthermia (MNPH) was used as a treatment in
the glioma model.104
The most important plain nanocarriers, employed in
in vivo preclinical studies for glioma non-invasive treat-
ment, are shown in Table 2.
Functionalized Nanocarriers
Nanocarriers can be functionalized on their surface with
suitable ligands, in order to exploit RMT and CMT at the
BBB. As previously mentioned, several specific recep-
tors, in particular for endogenous proteins and peptides,
were employed as molecular “Trojan horse” for nanocar-
rier systems.49 LDL receptor is overexpressed both at the
BBB and in glioma cells and, therefore, it is a potential
target to be exploited for the delivery of therapeutic
agents. Apolipoproteins (Apo) are usually employed to
target LDL receptors, but Apo being a high MW protein,
usually shorter chimera peptides including the receptor-
binding domain are employed.50,105 Angiopep-2
(TFFYGGSRGKRNNFKTEEY, molecular weight 2.4
kDa), a peptide belonging to the Kunitz domain-derived
family, is a potent ligand of LDL on the BBB employed
for nanocarriers functionalization.106 Within this concern,
it should be pointed out that Polysorbate 80 is frequently
employed as suspending agent for plain nanocarriers
aiming to drug brain delivery. Indeed, it has been
hypothesized that this nonionic surfactant can adsorb
endogenous Apo E present in serum on the surface of
nanoparticles.107,108 Mammalian Lf is a cationic iron
transporting glycoprotein (80 kDa), whose receptor is
expressed on the endothelial side of the BBB. Studies
with membrane preparations of mouse brain have shown
that the Lf receptor at the BBB has two classes of binding
sites: a high-affinity, with a dissociation constant Kd of
10.61 nM, and a low-affinity with a Kd of 2228 nM.
Plasmatic concentration of endogenous Lf (~5 nM) is
lower than the Kd of Lf receptors at the BBB. Thus, the
competitive inhibition with endogenous Lf is avoided,
allowing employment of Lf functionalized nanocarriers
for drug delivery in glioma models.109 Finally, apart from
protein ligands, nanocarriers can be functionalized also
with small molecules, recognized at the BBB from spe-
cific receptors/carriers, such as GSH receptor,110
folate receptor and monocarboxylic acid transporter
(MCT-1).61,111
However, different critical issues are associated with
active targeting to the BBB. First of all, most of the RMT
are not present exclusively at the BBB. For example, Tf
receptor is expressed in monocytes, red blood cells, lungs,
hepatocytes, and in the gut, along with the BBB. Within
this concern, it is reported that active targeting of nano-
carriers should benefit from employment of a “spacer”
between the nanoparticles’ surface and the grafted protein,
and that grafting a low amount of protein should enhance
selectivity for the BBB rather than nontarget tissues.51
Moreover, nanocarriers grafted with physiological ligands
(ie Tf) undergo binding competition with the correspond-
ing endogenous protein, which can decrease targeting
efficacy;46 then, most of the available targeting proteins
can cause immunogenic reactions; finally, some receptors
on the BBB, such as insulin and Tf, control homeostasis of
iron and glucose within the brain, and nanocarriers grafted
with monoclonal antibodies against these receptors may
down-regulate their activity and raise safety concerns.112
Functionalization of nanocarriers can be exploited also
to target specific receptors overexpressed in glioma and/or
at the BBTB. Previously mentioned overexpression of
EGFR and EGFRvIII mutant at the BBTB allows
a selective targeting.113 Also, integrins play important
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Table 2 Plain Nanocarriers Aiming to Glioma Therapy Employed in Preclinical Studies
Nanocarriers Drug Experimental in vivo Model Achievements in vivo References
AgNPs combined with
MNPH
Ag+ Efficacy in glioma rat model Enhanced Bcl-2-associated X protein expression [104]
Cationic SLN PEGylated
c-Met siRNA
Efficacy in U87 xenografts Enhanced accumulation in brain tumour and
down-regulation of c-Met levels
[93]
Liposomes Oxaliplatin Biodistribution and survival
analysis in F98/Fischer glioma
model
Increased brain oxaliplatin concentration and
median survival time of glioma models
[167]
NLC TMZ; GFP
encoding
pDNA
Efficacy in U87 xenografts Gene transfection and enhanced antitumor
activity
[96]
PLGA nanoparticles,
SLN, NLC
TMZ Efficacy in U87 xenografts Best efficacy obtained with NLC formulation [168]
Polymer nanogel miRNA
miR.34a
Efficacy in U87 xenografts Significant tumor growth inhibition [169]
Polysorbate 80 coated
PBCA nanoparticles
DOX Biodistribution in glioma models Increased accumulation of DOX in brain tumour [170]
Polysorbate 80 coated
PBCA nanoparticles
TMZ Biodistribution in healthy rats Increased brain uptake of TMZ [171]
Polysorbate 80 coated
PBCA nanoparticles
Gemcitabine Survival analysis in C6/Sprague
Dawley rat glioma models
Prolonged survival of glioma models [172]
Polysorbate 80 coated
PLA nanoparticles
TMZ Pharmacokinetic and
biodistribution in rats
Enhancement in half-life of TMZ with higher
deposition in the brain
[173]
Polysorbate 80 coated
SLN
CPT Pharmacokinetic and
biodistribution in rats
Increased brain accumulation of CPT [108]
Polysorbate 80 coated
SPION
DOX Biodistribution and efficacy in C6/
Sprague Dawley glioma model
Enhanced brain accumulation of SPION and
increased anti- tumour efficacy under magnetic
field
[174]
SLN PTX Rat brain perfusion experiment
after intra-carotid administration
Enhanced PTX accumulation in brain; P-gp
overcoming
[100]
SLN EDF Biodistribution and efficacy in
subcutaneous mouse model
Good drug accumulation in brain after oral
administration; P-gp overcoming
[101]
SLN DOX Pharmacokinetic and
biodistribution in rats and rabbits
Enhanced DOX accumulation in brain [175,176]
SLN Idarubicin Pharmacokinetic and
biodistribution in rats
Enhanced idarubicin accumulation in brain after
SLN oral administration
[103]
SLN, NLC TMZ;
vincristine
Efficacy in U87 xenografts Improved glioma inhibition with NLC and drug co-
delivery
[97]
Abbreviations: AgNPs, silver nanoparticles; Bcl-2, B-cell lymphoma 2; c-Met, tyrosine-protein kinase Met; C6, C6 cells; CPT, camptothecin; DOX, doxorubicin; EDF,
edelfosine; GFP, green fluorescent protein; miRNA, microRNA; MNPH, magnetic nanoparticle hyperthermia; NLC, nanostructured lipid carriers, PBCA, poly(butyl
cyanoacrylate); pDNA, plasmid DNA; PEG, polyethylenglycol; P-gp, P-glycoprotein; PLA, poly-lactide; PLGA, poly-lactide-glycolide; PTX, paclitaxel; siRNA, small interfering
RNA; SLN, solid lipid nanoparticles; SPION, superparamagnetic iron oxide nanoparticles; U87, U87 cells; TMZ, temozolomide.
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roles in tumour invasion and angiogenesis: in glioblastoma
avß3 and avß5 integrin receptors are overexpressed on
brain tumour cells and neo-vessels, favouring interaction
with the extracellular matrix. Integrins can be specifically
targeted by employing arginine-glycine-aspartic acid
(RGD) peptides, such as cilengitide (cyclo [RGDfV]),
a cyclic RGD peptide.114 Nucleolin, instead, exists only
in the nucleus of cells, thus offering an attractive target for
cells characterized from a high internalization rate. F3
peptide, that specifically binds to nucleolin, was utilized
to decorate nanocarriers, in order to realize glioma cell and
neo-vasculature dual-cellular targeting.115 Furthermore, as
previously mentioned, MMPs are a group of zinc-
dependent proteins acting as key modulators of tumour
invasion and metastatization, due to their degrading capa-
city of the extracellular matrix. In addition, MMP-2/9 is
also required for the tumoural angiogenic switch. Thus,
MMP-2/9 conjugated low-molecular-weight protamine
(ALMWP) was employed for glioma targeting of
nanocarriers.116 Also chlorotoxin (CTX), a small peptide
(36-amino acid) derived from Leiurus quinquestriatus
(scorpion) venom, can bind to MMP-2, and it was
employed for nanocarriers functionalization.117 Finally,
IL-13Ra2 receptor is overexpressed in pilocytic astrocyto-
mas and glioblastoma. Therefore, interleukin-13 (IL-13)
can be used to target nanocarriers to glioblastoma tissue.
A summary of the most important functionalized nano-
carriers employed in in vivo preclinical studies is shown in
Table 3, and a scheme of the main active targeting strate-
gies is displayed in Figure 4.
Nanocarrier-Mediated Cell Therapy
In addition to the selective BBB, glioma chemotherapy
can be hampered from the fact that it is difficult to obtain
a sufficiently high drug concentration in the tumour, in
order to kill infiltrative malignant cells, without hampering
healthy brain tissue. Thus, even if a relatively high drug
accumulation within brain tissue is obtained, chemother-
apeutics may undergo unwanted distribution in the extra-
cellular matrix, or within intratumoral necrotic pockets,
but without exerting the desired effects on target glioma
cells. These limitations may be overcome by using stem
cells as carriers of nanoparticulate delivery systems.118
Indeed, cell-based therapies represent an innovative and
valuable tool for cancer treatment, and recent interest is
growing also for high-grade glioma therapy. A number of
cells have been recently studied, either in preclinical or
clinical trials for brain tumour targeting, and can be
exploited also in combination with nanocarrier systems.
In particular, adult mesenchymal stem cells (MSC)
show a tumour tropic ability, that can be exploited simul-
taneously to target tumour and deliver therapeutic
agents.119 With genetic modification, MSC are able to
home cancer tissues and affect the tumor growth by the
secretion of cytotoxic molecules. Moreover, MSC are able
to trespass the BBB in physiological and pathological
conditions, and preclinical studies showed that MSC engi-
neered to express suicide gene enhance the antitumor
response in glioblastoma animal models. Within this con-
cern, the combinatorial approach of cell therapy, small-
molecule chemotherapy and nanomedicine strategies can
open new opportunities for glioma treatment (Figure 5).
Internalization/binding of drug-loaded nanoparticles into
MSC can be exploited to increase the antitumor efficacy
by targeted delivery to the tumour microenvironment.120
Indeed, PTX loaded PLGA nanoparticles showed an
enhanced activity in brain tumor, which is ascribed to the
sustained release of the drug.121 In a recent work, a hybrid
system consisting of MSC spheroids and methotrexate
(MTX)-loaded nanoparticles was engineered, in order to
increase retention at tumour site: this system improved
tumour inhibition in a heterotopic glioblastoma murine
model.122 Even though drug-loaded MSC are
a promising strategy, some major issues should be consid-
ered, such as the fact that the conjugation of nanodrugs to
MSC surface could affect the tumour homing ability, as
demonstrated by a lot of studies carried out on brain
tumour xenografts.
Interestingly, also adipose-derived stem cells (ADSC)
show tumour homing ability. This behaviour can be
exploited to design drug delivery systems for brain
tumours, such as cell-based carriers for nanoparticulate
systems. Moreover, it is possible to endow such nanopar-
ticles with stimuli-responsive properties for targeted drug
delivery. Indeed, superparamagnetic iron oxide nanoparti-
cles (SPION) were loaded with PTX and subsequently
taken up by ADSC via endocytosis.123 Drug release was
then activated by high-frequency magnetic field in
a glioblastoma murine model. The dual-modality therapeu-
tic strategy including ADSC and smart nanoparticles may
be further investigated in the near future for clinical
translation.
Given that the “immune privilege” of the brain is no
more a retained concept, also the recent advances in immu-
notherapy strategies offer new opportunities for a synergistic
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Table 3 Functionalized Nanocarriers Aiming to Glioma Therapy Employed in Preclinical Studies
Nanocarriers Drug Functionalization Experimental in vivo Model Achievements in vivo References
Polymeric
nanoparticles
TMZ Angiopep-2 Biodistribution of liposomes and
efficacy in C6/ICR mouse glioma
models
Enhanced brain distribution of
DOX and promising efficacy
in glioma models
[177]
Dendrimers TRAIL DNA Angiopep-2 Biodistribution of dendrimers and
survival analysis in C6 mouse
xenografts
Increased survival of
xenografts
[106]
PCL
nanoparticles
DOX Angiopep-2 Pharmacokinetics, biodistribution
and survival analysis in C6/Wistar
rat glioma models
Enhanced brain uptake of
DOX, prolonged survival of
glioma models
[178]
PLGA
nanoparticles
IP10 Angiopep-2; EGFRvIII
scFv
Efficacy in U87-EGFRvIII cells
xenografts
Reduced tumour growth,
prolonged survival of glioma
models
[179]
Liposomes Daunomycin Anti Tf Receptor
antibody
Pharmacokinetic & biodistribution
in rats
Increased daunomycin
accumulation in brain
[180]
Calcium
phosphate
nanoparticles
ATF5 siRNA Apo E Glioma distribution, ATF5
expression and survival analysis in
C6 mouse xenografts
Efficient tumour targeting and
increased survival of
xenografts
[181]
Polymersomes Saporin Apo E Biodistribution and efficacy in U87
mouse xenografts
Specific brain accumulation of
polymersomes, encouraging
efficacy towards brain
tumours
[182]
SLN MTX prodrug Apo E chimera
peptide
Biodistribution and survival analysis
in F98/Fischer rat glioma model
Increased brain accumulation
of MTX; encouraging efficacy
[50]
Lipid
nanoparticles
Porphyrin Apo E3 Pharmacokinetics and
biodistribution in mice, efficacy in
U87 mouse xenografts
Selective drug accumulation in
brain tumour compared to
healthy parenchyma
[183]
Liposomes – Cetuximab Biodistribution in U87 mouse
xenografts
Increased brain accumulation
of liposomes
[113]
Liposomes DOX Chlorotoxin Biodistribution of liposomes and
efficacy in U87 mouse xenografts
Brain accumulation of
liposomes, reduced tumour
growth
[117]
Polyionic
micelles
Cilengitide Cilengitide Survival analysis in C6/Wistar rat
glioma models
Prolonged survival of glioma
models
[184]
Polymeric
micelles
DACHPt Cilengitide Efficacy in U87 mouse xenografts Reduced tumour growth [185]
Liposomes DOX Cilengitide and
Peptide 22 (LDL
receptor)
Biodistribution and survival analysis
in intracranial glioma-bearing mice
Prolonged survival time of
glioma models
[114]
PEG−PLA
micelles
PTX EGFR/EGFRvIII
targeting peptide
Pharmacokinetics in healthy rats,
biodistribution and efficacy in U87
mouse xenografts
Specific micelles distribution
to the brain, reduced tumour
growth in glioma models
[186]
(Continued)
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Table 3 (Continued).
Nanocarriers Drug Functionalization Experimental in vivo Model Achievements in vivo References
PEG-PLA
nanoparticles
PTX F3 peptide (targeting
nucleolin) and tLyp-1
peptide (targeting
neuropilin)
Pharmacokinetics in rats;
biodistribution and survival analysis
in C6 mouse xenografts
Enhanced PTX accumulation
and deep penetration at the
tumour location; prolonged
survival in xenografts
[115]
PEGilated
liposomes
DOX GSH Pharmacokinetics, biodistribution
and efficacy in U87 mouse
xenografts
Enhanced brain retention of
DOX; strong inhibition of
brain tumour growth
[110]
Liposomes DOX IL-13 Efficacy in U251 mouse xenografts Reduced tumour growth in
glioma models
[187]
BSA
nanoparticles
DOX Lf Pharmacokinetics in rats,
biodistribution in C6/Wistar rat
glioma model
Increased brain uptake of
DOX
[188]
Cationic
liposomes
DOX Lf Biodistribution and survival analysis
in C6/Wistar rat glioma models
Increased accumulation of
DOX in brain and prolonged
survival time of glioma models
[109]
Liposomes 99mTc-BMEDA Lf Pharmacokinetic & biodistribution
in mice
Increased brain accumulation [189]
Olive oil
nanoparticles
TMZ Lf Pharmacokinetic & biodistribution
in healthy mice; biodistribution and
efficacy in GL261/C57BL/6 mouse
models
Enhanced brain distribution of
TMZ and promising efficacy
towards glioma
[190]
Olive oil
nanoparticles
Aurora Kinase
B siRNA
Lf Gene silencing and survival analysis
in GL261/C57BL/6 mouse models
Survival improvement of
glioma models treated with
nanoparticles and TMZ
simultaneously
[191]
PEG-PCL
polymersomes
DOX and
tetrandrine
Lf Pharmacokinetics, biodistribution
and efficacy in C6/Wistar rat
glioma model
Improved DOX distribution in
brain, reduced tumour growth
and increased survival in
glioma models
[192]
PEG-PLA
nanoparticles
PTX Lf and tLyp-1 peptide
(targeting neuropilin)
Pharmacokinetics in healthy rats,
biodistribution and efficacy in C6
mouse xenografts
Enhanced tumour
accumulation of PTX and
increased survival of glioma
models
[53]
NLC TMZ and
vincristine
Lf, RGD Biodistribution and efficacy in U87
xenografts
Specific brain distribution of
the drugs, promising efficacy
in glioma models
[193]
Liposomes DOX and
vincristine
T7 and DA7R Biodistribution of liposomes and
efficacy in C6/ICR mouse glioma
models
Enhanced brain distribution of
liposomes and promising
efficacy in glioma models
[194]
Liposomes 5-fluorouracil Tf Biodistribution of radiolabelled
liposomes in healthy rats
Increased brain uptake of
liposomes
[195]
(Continued)
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combination of cell therapy with chemotherapeutic drug
delivery systems, in order to target brain tumours.124 For
example, the combination of dendritic cell-targeted vaccines
with nanoparticles loaded with anticancer drugs should lead
to a superior anticancer activity.125 Combination with nano-
carrier loaded with checkpoint inhibitors could be another
valuable therapeutic approach.126 Furthermore, neutrophils
(NE) have a native ability to traverse BBB/BBTB and
penetrate the glioma site, where the tumour associated NE
favour the continuous recruitment of circulating NE; in
addition, local brain inflammation, following surgical
tumour removal, activates NE migration towards to the
inflamed brain. This amplification of inflammatory signals
supports an enhanced brain tumour targeting of nanocarriers
loaded in NE, such as PTX loaded liposomes127 and DOX
loaded magnetic mesoporous silica nanoparticles, which is
evident also in resection and recurrence orthotopic
models.128 Finally, chimeric antigen receptor (CAR)
T cells should be considered, too. They are T cells, generally
autologous, ex vivo artificially engineered on their surfaces
in order to recognize tumour-associated antigens. The CAR
shows both an antigen-binding and a T cell activating
function. These modified CAR T cells can produce the
lysis of the cells presenting the associated tumor antigen
when administered intravenously in patients. Currently,
CAR-T cell therapy has been approved in B-cell lymphoma
and leukemia, but clinical trials are ongoing for glioblastoma
treatment.129,130 Very recently CAR T cell administration
showed to improve anti-glioma response.131 Also in this
case, CAR-T cells could be associated with nanocarriers in
order to improve the therapeutic outcome, and CAR-T cell
surface can also be modified to targeting purposes. Indeed,
human epidermal growth factor receptor 2 (HER-2) functio-
nalized CAR T cells demonstrated increased persistence
over time.
Within this context, suitable attention should be
devoted also to cell membrane-coated nanoparticulate sys-
tems. Wrapping nanoparticles with cell-derived mem-
branes provide nanocarriers of a natural surface coating
with complex biological entities, which are nearly impos-
sible to synthetically replicate via ligand attachment. This
allows to overcome some of the previously mentioned
shortcomings of actively targeted nanocarriers, such as
opsonization and incorrect ligand recognition. Cell
Table 3 (Continued).
Nanocarriers Drug Functionalization Experimental in vivo Model Achievements in vivo References
Liposomes TMZ and
bromodomain
inhibitor
Tf Biodistribution in mice and efficacy
in U87 mouse xenografts and
C57BL/6 mouse models
Improved liposomes
distribution to the brain;
promising efficacy in glioma
models
[196]
SLN MTX prodrug Tf, Insulin Biodistribution in healthy rats Increased brain accumulation
of MTX
[51]
Liposomes DOX Tf, Octaarginin Biodistribution of liposomes and
efficacy in U87 mouse xenografts
Prolonged survival of glioma
models
[197]
SLN Docetaxel HBA Pharmacokinetics and
biodistribution in healthy rats
Enhanced drug brain uptake [111]
SLN Docetaxel
ketoconazole
Folic acid Pharmacokinetics and
biodistribution in healthy rats
Enhanced drug brain uptake;
P-gp overcoming
[61]
PEG-co-PCL
nanoparticles
PTX Activatable LMWP
coupled to a MMP-2/
9-cleavable peptide
sequence
Pharmacokinetics in rats;
biodistribution and efficacy in C6
mouse xenografts
Specific PTX accumulation in
glioma; enhanced efficacy in
xenografts
[116]
Abbreviations: 99mTc-labeled N,N-bis(2-mercaptoethyl)-N’,N’-diethylethylenediamine (99mTc-BMEDA); Apo, apolipoprotein; ATF5, activating transcription factor-5; C6, C6
cells; DA7R, DADTDWDLDPDPDR sequence, which has a high affinity for VEGFR 2; DACHPt, (1,2-diaminocyclohexane)platinum(II); DOX, doxorubicin; EGFR, epidermal
growth factor receptor; EGFRvIII, mutant EGFR; F98, F98 cells; GL261, GL261 cells; GSH, glutathione; HBA, β-hydroxybutyric acid; IP10, Interferon-γ-inducible protein;
LDL, low density lipoprotein; Lf, lactoferrin; LMWP, low-molecular-weight protein; MMP, matrix metalloproteinase; MTX, methotrexate; NLC, nanostructured lipid carriers;
PCL, poly(ε-caprolactone); PEG, polyethylenglycol; P-gp, P-glycoprotein; PLA, poly-lactide; PLGA, poly-lactide-glycolide; PTX, paclitaxel; RGD, arginine-glycine-aspartic acid;
scFv, single-chain Fv fragments; siRNA, small interfering RNA; SLN, solid lipid nanoparticles; T7, HAIYPRH sequence, which can bind to Tf receptors; Tf, transferrin; TMZ,
temozolomide; TRAIL, tumor necrosis factor (TNF) related apoptosis-inducing ligand; U251, U251 cells; U87, U87 cells.
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membrane coating technology was firstly introduced by
employing red blood cell membranes, in order to provide
“stealth” properties to synthetic nanoparticles. Currently, it
has been applied to many cell types, including cancer
cells.132 Indeed, cancer cells possess the unique ability to
self-target homologous cells (the so-called homotypic tar-
geting), which can be translated to wrapped nanocarriers,
showing also reduced immune clearance compared to
uncoated ones (Figure 6). Recently, in a study involving
PLGA nanoparticles coated with U87 glioma cell mem-
brane fractions, an induction of cancer cell-specific
immune response was demonstrated.133
Clinical Nanomedicines
Despite relevant evidences at the preclinical level, and sev-
eral clinical studies addressing the employment of nanocar-
riers for brain tumours chemotherapy, particularly for
glioblastoma, till now no new nano-drug has yet approved
for brain tumour therapy. In general, the approval rate for
novel nanomedicines is below 10%, mainly because of safety
and efficacy profile failures during preclinical and clinical
studies.134 Indeed, regulatory agencies require manufacturers
to perform accurate preauthorization studies to assess the
quality, safety, and efficacy profiles of a new
nanomedicine.135,136 Furthermore, the difficulty to find out
suitable preclinical models that truly represent what happens
in the humans is a major flaw, that hampers clinical transla-
tion of nanomedicines.95
Within this concern, according to the European
Commission Recommendation (2011/696/EU), 100 nm is
the demarcating upper size limit where the properties of
materials can change significantly from conventional
equivalents, and the European Medicines Agency (EMA)
also included an official definition of nanomedicine as
being up to a size of 100 nm.137 However, frequently
nanomedicines have broader size range than the proposed
Figure 4 Scheme of the main mechanism used for active targeting of nanocarriers in glioma therapy. Blue: endogenous ligands; red: exogenous ligands.
Abbreviations: avß3/avß5, avß3/avß5 heterodimers; CTX, chlorotoxin; EGFR, epidermal growth factor receptor; GSH, glutathione; HFE, homeostatic iron regulator
protein; IL 13, interleukin 13; LDL, low-density lipoprotein; Lf, lactoferrin; MCT-1, monocarboxylic acid transporter 1; MMP, matrix metalloproteinase; Tf, transferrin.
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definition, inducing the EMA to include all “structures”
with sizes of less than 1000 nm, that are designed to have
specific properties,138 can improve site-specific drug deliv-
ery and significantly alter toxicological profiles, thus
allowing to perform a case-by-case evaluation.139
Nonetheless, despite the numerous guidelines existing for
the validation methods of chemical parameters in such
matrixes, suitable implementation of this legislation
should require validated analytical methods for nanoparti-
cles’ characterization, that, so far, do not exist.140
Some of the most important clinical trials with new
emerging nanomedicines are here reported. Few of them
involve active targeting mechanisms. In fact, despite the
existence of good manufacturing practices for nanodrug
delivery systems, that can be employed for translation to
clinical trials,141 actively targeted nanomedicines are asso-
ciated with high costs and scale-up issues. A Phase
I clinical study involving patients with recurrent glioma
(grade 2–4) has been carried out by administering PTX-
Angiopep-2 peptide–drug conjugate (GRN1005). Even if
GRN1005 improved PTX permeation into tumour tissue,
Phase II trial interim analysis did not show therapeutic
response.142,143 Tf conjugated diphtheria toxin (Tf-
CRM107) showed in vitro toxicity towards glioma cells
and it was effective in xenografts after local administra-
tion. Moreover, in phase I and II clinical trials, local
administration of Tf-CRM107 resulted in low toxicity,
encouraging response rate (35%) and promising overall
survival (74 weeks) in patients with recurrent high-grade
brain tumours. However, early Phase III clinical trials
employing this approach were terminated due to disap-
pointing preliminary results.9,144 In another interesting
phase I study, EnGeneIC delivery vehicle loaded with
DOX was tested in patients with recurrent glioblastoma.
The anti-EGFR monoclonal antibody Vectibix was used to
target EGFR on cancer cells, thus leading to DOX
release.145
However, the most important clinical evidences were
obtained with off-label employment of already marketed
liposomal DOX, acting mainly owing to the EPR effect.
In a clinical study liposomal DOX administered in
patients with high-grade gliomas improved overall
survival.146 Moreover, DOX loaded in pegylated lipo-
somes (PEG-DOX) was efficacious and well tolerated in
patients with recurrent high-grade glioma.147 Indeed,
encouraging results were obtained with PEG-DOX
alone (mOS 26 weeks) or in combination with TMZ
(median overall survival 32 weeks, 6-months progres-
sion-free survival 32%). Owing to the available studies,
PEG-DOX, alone or in combination regimens, can actu-
ally be considered as a treatment option for recurrent
high-grade gliomas, but only if no further chemotherapy
is available; however, it should be further evaluated in
larger clinical trials.148
Figure 5 Scheme of nanocarrier mesenchymal stem cells (MSC) combined therapy of gliomas.
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Conclusions
Malignant gliomas are still associated with a poor prog-
nosis, despite recent advances in surgical treatment.
Despite the large number of potential drug candidates,
the efficacy of adjuvant chemotherapy remains unsatisfac-
tory, primarily because of the BBB. Nanocarriers can
favour delivery of chemotherapeutics to malignant gliomas
owing to different mechanisms, including chemical stabi-
lization of the drug in the bloodstream, EPR effect
(because of the leaky BBTB), P-gp inhibition, active tar-
geting through CMT and RMT, inhibition of cell differ-
entiation and angiogenesis, cell-mediated targeting, or
stimuli-responsive delivery. In particular, different and
efficient active targeting approaches have been attempted
in preclinical studies on animal models, mainly by
employing protein targeting moieties. Nevertheless, a few
number of nanomedicines reached the clinical trials, and
most of them include drug-loaded nanocarriers free of
targeting ligands, probably because of safety and scalabil-
ity concerns.
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